Approvals· September 5, 2026 · 29 min read
Topic
HER2
HER2-targeted therapy, oncology biosimilars, antibody-drug conjugates, coding, and access strategy.
Pricing & Access· August 18, 2026 · 18 min read
Ziihera's August 25 Gastric Decision: Bispecific vs Trastuzumab Biosimilars
By Ran Chen#Oncology#HER2#Biosimilars
Deals· July 23, 2026 · 17 min read
Novartis Ends Last Big-Pharma ADC Holdout: The $1.5B Myricx Deal
Pipeline· July 22, 2026 · 17 min read
Antibody-Drug Conjugate (ADC) Clinical Trials by the Numbers (2026)
By Ran Chen#ADC#Oncology#Clinical Trials
Pricing & Access· July 1, 2026 · 17 min read
CDK4/6 Inhibitor Access Landscape: Payer Dynamics After Ibrance's Expansion
By Ran Chen#Oncology#Breast Cancer#Payer Coverage
Pipeline· May 27, 2026 · 7 min read
Antibody-drug conjugate access landscape: ADC coverage and pipeline watch
By Ran Chen#ADC#HER2#Prior Authorization